aggressive cancer with high mortality and recurrence rates. Hecogenin, a steroidal sapogenin, is reported as a potential anti-tumor agent against breast cancer. However, the moderate activity limits its further application in clinical. With the aim to identify novel analogues that are especially efficacious in therapy of TNBC, a series of novel hecogenin thiosemicarbazone and semicarbazone derivatives were
三阴性乳腺癌(T
NBC)是最具侵袭性的癌症之一,具有高死亡率和复发率。Hecogenin 是一种甾体
皂苷元,据报道是一种潜在的抗乳腺癌药物。然而,中等活性限制了其在临床上的进一步应用。为了鉴定对 T
NBC 治疗特别有效的新类似物,设计、合成和
生物学评估了一系列新的 hecogenin 缩
氨基
硫脲和缩
氨基
脲衍
生物。细胞毒性筛选显示,4c可以在低 μM
水平有效抑制乳腺癌细胞(MCF-7 和
MDA-MB-231 细胞)、肺癌细胞(A549)和结肠癌细胞(HT-29)的增殖。重要的是,进一步的机制研究表明4c通过阻止细胞周期诱导
MDA-MB-231 细胞凋亡。此外,与相同浓度的亲本hecogenin相比,4c显着抑制
MDA-MB-231细胞的迁移和侵袭。